The cancer vaccine gold rush has begun. So has the race for picks and shovels.
Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the ...
finance.biggo
Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation
Moderna and Merck's personalized mRNA cancer vaccine mRNA-4157 achieved a breakthrough in Phase 3 trials, triggering a sharp ...
Christy Santhosh
The latest international Christy Santhosh news and views from Reuters - one of the world's largest news agencies ...
The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI
Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor ...
Tempus AI gains as Cantor issues new Overweight on Data and applications segment
Tempus AI (TEM) stock rises as Cantor Fitzgerald launches coverage with an overweight recommendation, citing the company's ...
Tempus AI Got an $80 Target and 28% Upside Call. Is Wall Street Underestimating Its Healthcare Data Moat?
Tempus AI received a fresh vote of confidence on September 2 as Cantor Fitzgerald initiated coverage with an Overweight rating and an $80 price target. From the roughly $62.27 price cited with the ...